Literature DB >> 6116636

Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients.

S J Konturek, W Obtułowicz, N Kwiecień, B Kopp, J Oleksy.   

Abstract

The dynamics of the inhibitory effect of ranitidine, a new H2-receptor antagonist, on histamine and pentagastrin-induced gastric secretion have been examined in duodenal ulcer patients. The inhibition by ranitidine of histamine-induced secretion was found to be competitive, whereas that of pentagastrin-induced secretion not competitive. Ranitidine was an effective inhibitor of pentagastrin-induced secretion for 8-12 h after administration. The availability of ranitidine, a powerful and long-acting inhibitor of gastric secretion, provides an opportunity of an alternative treatment from cimetidine for peptic ulcer and related diseases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116636     DOI: 10.1159/000198617

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

1.  Tolerance to oral H2-receptor antagonists.

Authors:  C H Wilder-Smith; T Ernst; M Gennoni; B Zeyen; F Halter; H S Merki
Journal:  Dig Dis Sci       Date:  1990-08       Impact factor: 3.199

2.  Prevention of duodenal ulcers in the rat using a combination of ranitidine and sucralphate in subtherapeutic doses.

Authors:  S Bank; H Zimmerman; C Smolow; V Kranz
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

Review 3.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

4.  Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.

Authors:  J L Smith; M A Gamal; A N Chremos; D Y Graham
Journal:  Dig Dis Sci       Date:  1985-04       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.